{
  "question_stem": {
    "en": "A group of researchers conduct a study to evaluate the pharmacologic properties of oxfendazole, an anthelmintic agent. As part of the study, increasing oral doses of oxfendazole (0.5 to 60 mg/kg) are administered to healthy volunteers. Data is collected to form a pharmacokinetic profile of the drug and its metabolites, and the incidence of adverse effects is recorded for the various dosages. A total of 20 healthy male and female (nonchildbearing potential) volunteers participate in the study. Oxfendazole is found to be well tolerated throughout the dose range without any serious adverse effects or deaths.",
    "zh": "一组研究人员进行了一项研究，以评估驱虫药奥芬达唑的药理特性。作为该研究的一部分，向健康志愿者口服给予递增剂量的奥芬达唑（0.5 至 60 mg/kg）。收集数据以形成该药物及其代谢物的药代动力学特征，并记录不同剂量的不良反应发生率。共有 20 名健康男性和女性（无生育能力）志愿者参与了这项研究。 结果发现，奥芬达唑在整个剂量范围内耐受性良好，没有出现任何严重不良反应或死亡。"
  },
  "question": {
    "en": "Which of the following best describes this type of study?",
    "zh": "以下哪项最能描述这种研究类型？"
  },
  "options": {
    "A": {
      "en": "Preclinical study",
      "zh": "临床前研究"
    },
    "B": {
      "en": "Phase I clinical trial",
      "zh": "I 期临床试验"
    },
    "C": {
      "en": "Phase II clinical trial",
      "zh": "II 期临床试验"
    },
    "D": {
      "en": "Phase III clinical trial",
      "zh": "III 期临床试验"
    },
    "E": {
      "en": "Phase IV clinical trial",
      "zh": "IV 期临床试验"
    }
  },
  "correct_answer": "B",
  "explanation": {
    "en": "The clinical trials process addresses whether new treatments (eg, drugs, procedures) are effective and safe for their intended use (ie, treatment of a disease) in the target population (eg, subjects with the disease of interest). New treatments go through several research phases; some phases involve no human subjects (ie, preclinical studies) and some involve few (ie, phase I and II trials) or many (ie, phase III and IV trials) human subjects. Each of these phases has a different purpose.\n\nA phase I trial is the first step in testing a new treatment in humans. Data is collected on the drug's pharmacokinetic profile, metabolism, and pharmacodynamic response (ie, how it affects the body). Different treatment routes (eg, orally, intravenously) may also be investigated. Human safety is assessed in terms of adverse effects and the maximum tolerated dose (MTD). Gradually increasing doses are typically administered to find the highest dose (ie, MTD) that does not cause unacceptable toxicity. Phase I trials usually include only a small number of healthy subjects.\n\nNote: Cancer-related phase I trials may involve subjects with cancer (rather than healthy subjects) who have been unresponsive to other treatments.\n\n(Choice A) Contrary to phase I, II, III, and IV trials, which include human subjects, preclinical studies do not involve human subjects.\n\n(Choice C) A phase II trial assesses treatment efficacy in a small number of affected subjects (ie, those with the disease of interest), rather than in healthy subjects. For example, a phase II study would assess efficacy, optimal dosing, and adverse effects of oxfendazole among subjects with helminth infection. The study above evaluated the safety, pharmacokinetic profile, and metabolism of oxfendazole in a small number of healthy subjects.\n\n(Choice D) A phase III trial assesses the safety and effectiveness of a new treatment compared to a standard treatment (or placebo); therefore, it involves ≥2 groups of affected subjects. For example, a phase III study would evaluate the effectiveness of oxfendazole compared to placebo among subjects with helminth infection.\n\n(Choice E) A phase IV trial studies the adverse effects caused over time by a new treatment after it has been approved and is on the market, as with a study to assess adverse effects related to oxfendazole use not seen in earlier trials.\n\nEducational objective:\nA phase I trial assesses the pharmacokinetics, pharmacodynamics, and safety profile (eg, adverse events, toxicity) of a new treatment in humans. It is usually conducted on a small number of healthy subjects.",
    "zh": "临床试验过程旨在确定新的治疗方法（例如，药物、程序）在目标人群（例如，患有相关疾病的受试者）中是否对其预期用途（即，治疗疾病）有效且安全。新的治疗方法要经过几个研究阶段；一些阶段不涉及人类受试者（即，临床前研究），而另一些阶段涉及少量（即，I 期和 II 期试验）或大量（即，III 期和 IV 期试验）人类受试者。这些阶段各有不同的目的。\n\nI 期试验是在人体中测试新治疗方法的第一步。收集关于药物的药代动力学特征、代谢和药效学反应（即，它如何影响身体）的数据。还可以研究不同的给药途径（例如，口服、静脉注射）。通过不良反应和最大耐受剂量 (MTD) 来评估人体安全性。通常逐渐增加剂量以找到不会引起不可接受毒性的最高剂量（即，MTD）。I 期试验通常只包括少数健康受试者。\n\n注意：与癌症相关的 I 期试验可能涉及对其他治疗无反应的癌症患者（而不是健康受试者）。\n\n（选项 A）与涉及人类受试者的 I 期、II 期、III 期和 IV 期试验相反，临床前研究不涉及人类受试者。\n\n（选项 C）II 期试验评估治疗在少数受影响受试者（即，患有相关疾病的受试者）中的疗效，而不是在健康受试者中。例如，一项 II 期研究将评估奥芬达唑在患有蠕虫感染的受试者中的疗效、最佳剂量和不良反应。上述研究评估了奥芬达唑在少数健康受试者中的安全性、药代动力学特征和代谢。\n\n（选项 D）III 期试验评估新治疗方法与标准治疗方法（或安慰剂）的安全性及有效性；因此，它涉及 ≥2 组受影响的受试者。例如，一项 III 期研究将评估奥芬达唑与安慰剂在患有蠕虫感染的受试者中的有效性。\n\n（选项 E）IV 期试验研究在新的治疗方法获得批准并在市场上销售后，由其随时间引起的不良反应，例如，一项研究评估与奥芬达唑使用相关的不良反应，这些不良反应在早期的试验中未被发现。\n\n教育目标：\nI 期试验评估新治疗方法在人体中的药代动力学、药效学和安全性特征（例如，不良事件、毒性）。它通常在少数健康受试者身上进行。"
  },
  "summary": {
    "en": "This question tests knowledge of the different phases of clinical trials, specifically the purpose and characteristics of a Phase I clinical trial. It requires understanding the goals of each phase in drug development and the types of subjects involved.\n\nTo solve this question, focus on the key aspects of the study described: healthy volunteers, increasing doses, and assessment of safety and pharmacokinetics. These features are characteristic of a Phase I clinical trial, which aims to determine the safety and dosage of a new drug in humans.",
    "zh": "这个问题考察了对不同临床试验阶段的了解，特别是 I 期临床试验的目的和特征。它要求理解药物开发中每个阶段的目标以及涉及的受试者类型。\n\n为了解决这个问题，重点关注所描述研究的关键方面：健康志愿者、递增剂量以及对安全性和药代动力学的评估。这些特征是 I 期临床试验的特征，其目的是确定新药在人体中的安全性和剂量。"
  },
  "tags": "Clinical trials; Drug development; Phase I trial; Pharmacokinetics; Drug safety; Biostatistics",
  "category": "Bio",
  "question_id": "19388",
  "has_exhibits": false,
  "exhibit_count": 0,
  "exhibit_files": [],
  "folder_path": "C:\\Datas\\usmle\\step1\\clip\\Bio & Statistics 23\\19388",
  "extracted_at": "2025-11-05T13:21:21.902767",
  "extraction_config": {
    "temperature": 0.1,
    "top_k": 1,
    "prompt_strategy": "standard"
  },
  "translated_at": "2025-11-07T16:22:37.350432",
  "translation_model": "gemini-2.0-flash-lite",
  "embedding_model": "models/embedding-001",
  "embedding_dimension": 768
}